Bruce Campbell (2) Green Thumb Industries GTII-CSE TOP PICK Oct 21, 2022

The rare American cannabis stock, mostly in medical marijuana. They report Wednesday and he expects positive results. Be careful though, because cannabis stocks are way up now, overbought. If Biden wins, thought, it will be a tailwind for the US cannabis industry.

Allan Tong’s Discover Picks GTII had a rough Q1 earlier this year as operating EBITDA margin slid to 28%, though it recovered to 31% in Q2. Q1 also saw a 6% slide in comparable sales as inflation corroded any gains. In Q2, though, revenues climbed 5% and stabilized. Q1 same-store sales fell 6%. To be fair, the market sell-off has been particularly unkind to cannabis stocks. Curaleaf is the better buy here, but in the ever-changing world of weed, GTII is worth keeping on your watch list. Read 3 Cannabis Stocks to go Higher for our full analysis.

It has one of the strongest teams, some of the strongest assets and some of the strongest markets in the cannabis sector. The stock is recovering now with the underlying business continuing to grow. Some of the institutional managers could come back. It is possible for a glut in Cannabis in the U.S. as well as the one already in Canada but some states have limited licenses which is good for companies in those areas. Buy 22, Hold 0. Sell 0 (Analysts’ price target is $30.77)

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

With continued negative stock momentum, some debt, and not a lot of growth expected (estimated EPS this year less than 2021) it is hard to get too excited about GTII. There has been some insider buying which is a good sign, but the sector continues to struggle and the stock is down another 14% in January alone. US legislation would certainly help but seems a long time coming. We would not have a lot of interest here.
Unlock Premium - Try 5i Free